Effect of aminoguanidine on erythrocyte lipid peroxidation and activities of antioxidant enzymes in experimental diabetes

Clinical Chemistry and Laboratory Medicine

Volumn 36, Issue 10, 1998, Pages 771-775

  Kȩdziora Kornatowska, Kornelia Z ^a   Luciak, Marek ^a   Błaszczyk, Jan ^a   Pawlak, Wojciech ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Aminoguanidine; Catalase; Diabetes; Glutathione peroxidase; Lipid peroxidation; Superoxide dismutase

Indexed keywords

AMINOGUANIDINE; CATALASE; GLUCOSE; GLUTATHIONE PEROXIDASE; HEMOGLOBIN A1C; MALONALDEHYDE; STREPTOZOCIN; SUPEROXIDE DISMUTASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; ENZYME ACTIVITY; ERYTHROCYTE; GLUCOSE BLOOD LEVEL; INTRAPERITONEAL DRUG ADMINISTRATION; LIPID PEROXIDATION; MALE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; STREPTOZOCIN DIABETES; TIME;

ANIMALS; BLOOD GLUCOSE; BODY WEIGHT; CATALASE; DIABETES MELLITUS, EXPERIMENTAL; ERYTHROCYTES; GLUTATHIONE PEROXIDASE; GUANIDINES; HEMOGLOBIN A, GLYCOSYLATED; LIPID PEROXIDATION; MALONDIALDEHYDE; RATS; RATS, WISTAR; STREPTOZOCIN; SUPEROXIDE DISMUTASE;

ANIMALIA;

EID: 0345404480     PISSN: 14346621     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Brownlee M. Glycation products and the pathogenesis of diabetic complications. Diabetes Care 1992; 15:1835-43.
2. Winegard AL. Banting Lecture 1986: Does a common mechanism induce the diverse complications of diabetes? Diabetes 1987; 36:396-406.
3. Jennings PE, Barnett AM. New approaches to the pathogenesis and treatment of diabetic microangiopathy. Diabetic Med 1988; 5:111-7.
4. Sinclair AJ. Free radical mechanisms and vascular complications of diabetes mellitus. Diabetes Rev 1993; 2:7-10.
5. Bono A, Caimi G, Catania A, Sarno A, Pandolfo L. Red cell peroxide metabolism in diabetes mellitus. Horm Metab Res 1987; 19:264-6.
6. Sato Y, Hotta N, Sakamoto N, Matsuaka S, Ohnishi N, Yagi K. Lipid peroxide level in plasma of diabetic patients. Biochem Med 1979; 21:104-7.
7. Jain SK, McVie R, Dvett J, Herbst JJ. Erythrocyte membrane lipid peroxidation and glycosylated hemoglobin in diabetes. Diabetes 1989; 38:1539-43.
8. Yagi K. Lipid peroxides and human diseases. Chem Phys Lipids 1987; 45:337-51.
9. Jain SK. Hyperglycemia can cause membrane lipid peroxidation and osmotic fragility in human red blood cells. J Biol Chem 1989; 264:21340-5.
10. Brown CD, Zhao ZH, De Alvaro F, Chan S, Friedman EA. Correction of erythrocyte deformability defect in ALX-induced diabetic rabbits after treatment with aminoguanidine. Diabetes 1993; 42:590-3.
11. Baba Y, Kai M, Kamada T, Setoyama S, Otsuji S. Higher levels of erythrocyte membrane microviscosity in diabetes. Diabetes 1979; 28:1138-40.
12. Wolff SP, Dean RT. Glucose autoxidation and protein modification: the potential role of autoxidative glycosylation in diabetes. Biochem J 1987; 245:243-50.
13. Brownlee M, Cerami A, Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complication. N Engl J Med 1988; 318:1315-20.
14. Mullarkey C, Edelstein D, Brownlee M. Free radical generation by early glycation end products: a mechanism for accelerated atherogenesis in diabetes. Biochem Biophys Res Comm 1990; 173:932-9.
15. Hori O, Yan SD, Ogawa S, Kuwabara K, Matsumoto M, Stern D, ef al. The receptor for advanced glycation end-products has a central role in mediating the effects of advanced glycation end products on the development of vascular diseases in diabetes mellitus. Nephrol Dial Transplant 1996; 11 (Suppl. 5):13-6.
16. Baynes JW. Perspectives in diabetes: role of oxidative stress in development of complications in diabetes. Diabetes 1991; 40:405-12.
17. Barnett AH. Pathogenesis of diabetic microangiopathy: an overview. Am J Med 1991; 90 (Suppl. 6A):67-73.
18. Chang KC, Chung SY, Chong WS, Sun JS, Kim SH, Noh HK, et al. Possible superoxide radical-induced alteration of vascular reactivity in aortas from streptozotocin-treated rats. J Pharmacol Exp Ther 1993; 266:992-1000.
19. Ha H, Kim KH. Role of oxidative stress in the development of diabetic nephropathy. Kidney Int 1995; 48:18-21.
20. Uzel N, Sivas A, Uysal M, Öz H. Erythrocyte lipid peroxidation and glutathione peroxidase activities in patients with diabetes mellitus. Horm Metab Res 1987; 19:89-90.
21. Chow CK. Vitamin E and oxidative stress. Free Radic Biol Med 1991; 11:215-32.
22. Asayama K, Uchida N, Nakane T, Hayashibe H, Dobashi H, Amemiya K, et al. Antioxidants in the serum of children with insulin-dependent diabetes mellitus. Free Radic Biol Med 1993; 15:597-602.
23. Wohaieb SA, Godin DV. Alterations in free radical tissue defense mechanisms in streptozotocin-induced diabetes in rat. Diabetes 1987; 36:1014-8.
24. Hammes HP, Martin S, Federlin K, Geisen K, Brownlee M. Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy. Proc Natl Acad Sci USA 1991; 88:11555-8.
25. Tajiri Y, Möller C, Groll V. Long term effects of aminoguanidine on insulin release and biosynthesis: evidence that formation of advanced glycosylation end products inhibits B cell function. Endocrinology 1997; 138:273-80.
26. Edelstein D, Brownlee M. Mechanistic studies of advanced glycation end products inhibition by aminoguanidine. Diabetes 1992; 41:26-9.
27. Fu MX, Wells-Knecht KJ, Blackledge JA, Lyons TJ, Thorpe SR, Baynes JW. Glycation, glycoxidation and cross-linking of collagen by glucose. Kinetics, mechanism and inhibition of late stages of Maillard reaction. Diabetes 1994; 43:676-83.
28. Asayama K, Hayashibe H, Dobashi K, Niitsu T, Miyao A, Kato K. Antioxidant enzyme status and lipid peroxidation in various tissues of diabetic and starved rats. Diabetes Res 1989; 12:85-91.
29. Jain SK, Levine SN, Duett J, Hollier B. Elevated lipid peroxidation levels in red blood cells of streptozotocin-treated diabetic rats. Metabolism 1990; 39:971-5.
30. Picard S, Parthasaraty S, Fruebis J, Witztum JL. Aminoguanidine inhibits oxidative modification of low density lipoprotein and the subsequent increase in uptake by macrophage scavenger receptor. Proc Natl Acad Sci USA 1992; 89:6876-80.
31. Corbett JA, Tilton RG, Chang K, Hasan KS, Ido Y, Wang JL, et al. Aminoguanidine, a novel inhibitor of nitric oxide formation, prevents diabetic vascular dysfunction. Diabetes 1992; 4:552-6.
32. Bell RH, Hye RJ. Animal models of diabetes mellitus: physiology and pathology. J Surg Res 1983; 35:433-60.
33. Misra HP, Fridovich I. The role of superoxide anion in the autoxidation of epinephrine and a simple assay for superoxide dismutase. J Biol Chem 1972; 247:3170-5.
34. Beers R, Sizer JW. Spectrophotometric method for measuring the breakdown of hydrogen peroxide by catalase. J Biol Chem 1952; 195:133-40.
35. Little C, O'Brien PJ. An intracellular GSH-peroxidase with a lipid peroxide substrate. Bioch Biophys Res Comm 1968; 31:145-50.
36. Young IS, Trimble ER. Measurement of malondialdehyde in plasma by high performance liquid chromatography with fluorimetric detection. Ann Clin Biochem 1991; 28:504-8.
37. Kawamura N, Ookawara T, Suzuki K, Konishi K, Mino M, Taniguchi N. Increased glycated Cu,Zn-superoxide dismutase levels in erythrocytes of diabetics with insulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1992; 74:1352-4.
38. Kakkar R, Mantha SV, Radih J, Prasad K, Kalra J. Antioxidant defense system in diabetic kidney: a time course study. Life Sci 1997; 60:667-79.
39. Thornalley P, Wolff S, Crabbe J, Sterm A. The autoxidation of glyceraldehyde and other simple monosaccharides under physiological conditions catalysed by buffer ions. Biochim Biophys Acta 1984; 9:25-33.
40. Vlassara H, Bucala R, Striker L. Pathogenic effects of advanced glycosylation: biochemical, biologic and clinical implications for diabetes and aging. Lab Invest 1994; 70:138-51.
41. Makita Z, Fuh H, Vlassara H. Circulating advanced glycosylation end-products (AGEs) react and promote oxidation of plasma LDL more efficiently than glucose. Diabetes 1993; 42:8A.
42. Soulis T, Cooper MF, Vranes D, Bucala R, Jerums G. Effects of aminoguanidine in preventing experimental diabetic nephropathy are related to the duration of treatment. Kidney Int 1996; 50:627-34.
43. Hammes HP, Brownlee M, Edelstein D, Saleck M, Martin S, Federlin K. Aminoguanidine inhibits the development of accelerated diabetic retinopathy in the spontaneous hypertensive rat. Diabetologia 1994; 37:32-5.
44. Cameron NE, Cotter MA, Dines K, Love A. Effects of aminoguanidine on peripheral nerve function and polyol pathway metabolites in streptozotocindiabetic rats. Diabetologia 1992; 35:946-50.
45. Brownlee M, Vlassara H, Kooney A, Ulrich P, Cerami A. Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. Science 1986; 232:1629-32.
46. Jain SK, Palmer M. The effect of oxygen radical metabolites and vitamin E on glycosylation of proteins. Free Radic Biol Med 1997; 22:593-6.
47. Ceriella A, Giugliano D, Quatraro A, Donzella C, Dipalo G, Lefebure PJ. Vitamin E reduction of protein glycosylation in diabetes. Diabetes Care 1991; 14:68-72.